2024-03-28T12:28:43Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/62512018-09-12T11:35:28Zcom_10261_112com_10261_1col_10261_365
00925njm 22002777a 4500
dc
Sánchez García, Isidro
author
Vicente-Dueñas, Carolina
author
Cobaleda, César
author
2007
In spite of the advances in our knowledge of cancer
biology, most cancers remain not curable with present
therapies. Current treatments consider cancer as resulting
from uncontrolled proliferation and are non-specific.
Although they can reduce tumour burden, relapse occurs
in most cases. This was long attributed to incomplete
tumour elimination, but recent developments indicate
that different types of cells contribute to the tumour
structure, and that the tumour’s cellular organization
would be analogous to that of a normal tissue, with a
main mass of differentiating cells sensitive to antiproliferative
agents, together with a small percentage of
quiescent, resistant stem cells responsible for replenishing
the tumour: the Cancer Stem Cells (CSCs). Anti-
CSCs targeted therapeutic agents would prevent
tumour regeneration. New mouse models tailored to
exploit this novel concept will be critical to develop
CSC-based anti-cancer therapies. Here we review the
biological basis and the therapeutic implications of
the stem-cell model of cancer.
Bioessays 29(12): 1269-1280 (2007)
0265-9247
http://hdl.handle.net/10261/6251
10.1002/bies.20679
The theoretical basis of cancer-stem-cell-based therapeutics of cancer: can it be put into practice?